Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim presents Viramune study data

Boehringer Ingelheim presents Viramune study data

25th July 2007

Boehringer Ingelheim has presented new data from an extended three-year follow-up analysis of the 2NN study and the Nile study of Viramune (nevirapine).

Exhibited at the fourth meeting of the International Aids Society in Sydney, the results from the first of these studies showed that patients administered with the compound showed a virologic and immunologic response comparable to that seen in patients receiving efavirenz.

In the second study, Viramune confirmed its ability to increase the levels of high-density lipoprotein (HDL) cholesterol – dubbed “good cholesterol” – in the body through 24 weeks of treatment.

Peter Reiss, professor of medicine at the Academic Medical Centre in Amsterdam, said: “These studies show how to further maximise the benefits of treatment with Viramune.

“The findings of the Nile study are particularly encouraging as it was thought that some therapies for HIV may increase cardiovascular risk.”

He added that the results of the Nile study indicate that the compound can increase the levels of HDL cholesterol in a way that may reduce the risk of cardiovascular disease, which could potentially result in the development of innovative drug candidates in this area.

In May 2007, Boehringer Ingelheim reported an amendment to its voluntary licensing policy for generic producers of nevirapine in order to broaden access to the anti-HIV drug in the developing world.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.